Premium
Serious Liver Injury Associated with Macitentan: A Case Report
Author(s) -
Tran Thao T.,
Brinker Allen D.,
Muñoz Monica
Publication year - 2018
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2078
Subject(s) - bosentan , medicine , adverse event reporting system , liver transplantation , fulminant hepatitis , endothelin receptor antagonist , adverse effect , food and drug administration , liver injury , ambrisentan , cardiology , endothelin receptor , hepatitis , transplantation , pharmacology , receptor
Several endothelin receptor antagonists ( ERA s) that were developed for the treatment of pulmonary arterial hypertension ( PAH ), including bosentan and sitaxentan, have been linked to clinically significant hepatocellular injury, as well as liver failure. We describe the first case of fulminant hepatitis to be reported in association with the ERA macitentan. This case was recently identified within the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and describes liver transplantation occurring 13 months after macitentan initiation in a young patient (23 years old) with idiopathic PAH New York Heart Association (NYHA) functional class III .